



Companies

Licensor
 Licensee

Potential Use

Disease Area
 Indication

Deal Financials

Potential Deal Size
 Upfront
 Milestones Total
 Milestones Regulatory
 Milestones Sales

Research Funding
 Profit Sharing Licensor
 Profit Sharing Licensee
 Royalties
 Equity

Compound

Compound Details
 Compound Name
 Development Stage

Territory
 Year of Deal Establishment
 Free Text Search

Filter Specification

179

OR

No.	Licensor	Potential Deal Size (mln) Amount	Upfront (mln) Remarks	Upfront (mln) Amount	Milestones total (mln) Remarks	Milestones total (mln) Amount	Milestones regulatory (mln) Remarks	Milestones regulatory (mln) Amount	Milestone: sales (mln) Remarks	Milestones sales (mln) Amount	Research Funding (mln) Rem...	Research Funding (mln) Amount	Profit sharing Remarks	Profit sharing % licensor	Profit sharing % licensee	Roy % 5 Rel
169	Vitae Pharmaceuticals	242	including equity and research funding	42		-		200		-	including upfront and equity	42		0	0	
170	Penwest Pharmaceutical Co./Endo Pharmaceuticals	-		2		2	Australian regulatory and sales milestones	1.1	1 for Canada; 1.1 for Australia includes regulator milesto...	2.1		0		0	0	
171	Transcept Pharmaceuticals	145		25		120	FDA approval	30	includes intellectual property milesto...	90		0		0	0	Additi double royalt psych co-prc optior exerci
172	NeuroSearch	-		5 per product		213		-		-	over 3 years	12		0	0	Double